Alchemab Therapeutics
PrivateLast Round
Series A
Extension
Jul 9, 2026
Total Funding Raised
$116M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Alchemab Therapeutics is a biotechnology company that develops novel therapeutic antibodies by analyzing patient antibody repertoires from disease-resilient individuals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alchemab Therapeutics Comparables
Compare Alchemab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoResponse | 78% | |
| Macomics | 75% | |
| Mestag Therapeutics | 71% |
Alchemab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 9, 2026 | ||||
| Series A Extension | Sep 9, 2025 | ||||
| Grant | Dec 16, 2022 | ||||
| Series A | Apr 15, 2021 | ||||
| Accelerator | May 12, 2020 |
Key People
Founding team and executive leadership
Alchemab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A Extension, Series A |
| SV Health Investors | Series A, Series A Extension, Seed |
| DCVC Bio | Seed, Series A Extension |
| Camford Capital | Series A |
| Lightstone Ventures | Series A, Series A Extension |
| British Business Bank | Series A Extension |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 60% MoM, reaching 4.6K.
- Jul 9, 2026
$34M round led by British Business Bank.
Recent news
Latest coverage and updates
- hiresSep 10, 2026
Alchemab hired Ben Porter-Brown as Chief Medical Officer on Sep 10th '26.
Alchemab Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alchemab Therapeutics's valuation, stock price, and market status.
Is Alchemab a public or private company?
Alchemab is a private company.
What is the current stock price of Alchemab?
Alchemab is a private company with no public stock price. No recent secondary market data is available.
How much is Alchemab worth (valuation)?
Valuation information for Alchemab is not publicly available.
Can I buy Alchemab stock?
Alchemab shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alchemab's last funding round?
Alchemab's most recent funding round was Series A Extension on September 10, 2025.
Who are the main investors in Alchemab?
Key investors in Alchemab include RA Capital Management, SV Health Investors.
Will Alchemab IPO soon?
No public IPO plans have been announced for Alchemab.
How can I track Alchemab secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alchemab's secondary market activity and sign up for updates.